Eton Pharmaceuticals announced the availability of Biorphen (phenylephrine HCl) injection as the first ready-to-use injectable formulation of phenylephrine.
Biorphen, an α-1 adrenergic receptor agonist, is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. It is supplied as a 0.1mg/mL solution in 5mL single-dose ampules; this corresponds to 0.5mg of phenylephrine HCl per ampule, equivalent to 0.41mg of phenylephrine base. As the product is a ready-to-use formulation, it must not be diluted before administration.
Biorphen is available in a pack of 10 ampules for ordering through wholesalers McKesson, AmerisourceBergen, and Cardinal Health and has a 3-year shelf life.
“The availability of Biorphen reduces the need for hospitals to rely on compounders to provide unapproved compounded phenylephrine,” said Sean Brynjelsen, President and CEO of Eton. “In addition, Biorphen’s 3-year shelf life allows hospitals to more easily stock the product in operating rooms, emergency rooms, and crash carts.“
For more information visit biorphen.com.